Nutraceutical targeting of the bile acid receptor, farnesoid X receptor, for intestinal disease.

Ciara M Fallon,Andrew Quach,Natalia Lajczak-McGinley,Jessica S Smyth, Caitriona E Curley,Karl Hazel,Karen Boland, Aoibhlinn O'Toole,Kim E Barrett,Helen Sheridan,Stephen J Keely

FASEB JOURNAL（2022）

引用 0|浏览7

暂无评分

摘要

Our data demonstrate that KFS1-containing plant extracts modulate expression and activity of FXR in the intestinal epithelium. Given the critical role of FXR in maintenance of gut health and metabolic function, such extracts have significant therapeutic and commercial potential to be developed as a novel first-in-class "FXR-targeted nutraceutical" for treatment and prevention of common intestinal disorders.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要